Trials / Recruiting
RecruitingNCT07297979
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Xaluritamig in Adult, Adolescent and Pediatric Participants With Relapsed or Refractory Ewing Sarcoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xaluritamig | Participants will receive xaluritamig via short-term intravenous (IV) infusion. |
Timeline
- Start date
- 2026-04-08
- Primary completion
- 2030-05-26
- Completion
- 2030-05-26
- First posted
- 2025-12-22
- Last updated
- 2026-04-16
Locations
3 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07297979. Inclusion in this directory is not an endorsement.